Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605533733 | ||
| 003 | CHVBK | ||
| 005 | 20210128100839.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10928-014-9398-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10928-014-9398-5 | ||
| 245 | 0 | 0 | |a Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice |h [Elektronische Daten] |c [Ryosuke Shimizu, Mikiko Kitade, Takashi Kobayashi, Shin-Ichiro Hori, Ayahisa Watanabe] |
| 520 | 3 | |a Second-generation antisense oligonucleotides (ASOs) demonstrate excellent biological stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for drugs to treat various diseases. A pharmacokinetic-pharmacodynamic (PK-PD) model of ASOs is desired for the design of appropriate PK and pharmacological studies. The objective of this study was to develop a PK-PD model to accurately simulate hepatic ASO concentration and its efficacy from plasma ASO concentration. After single subcutaneous administration of an ASO targeting hepatic apolipoprotein B (Apo-B) mRNA to mice, the ASO was absorbed rapidly and showed biphasic decline with time from the plasma and liver (t1/2: 1-3 and 81-183h, Tmax: 0.25-0.50 and 4-8h). After administration, hepatic Apo-B mRNA and plasma total cholesterol began decreasing at 4-8 and 8-24h, and their Tmax values were observed at 24-72 and 72h. To develop the PK-PD model based on the mechanisms of ASOs, we described the plasma and hepatic ASO concentration with linear two-compartment models. In addition, we inserted two indirect response models for mRNA and plasma total cholesterol. Model predictions from plasma ASO concentration gave excellent fits to the observed values of hepatic ASO concentration, Apo-B mRNA and plasma total cholesterol after single or multiple subcutaneous administrations. Our PK-PD model could accurately predict hepatic ASO concentrations and their efficacies from plasma ASO concentrations. This PK-PD model could be a useful tool for suggesting PK and pharmacological study protocols for various liver-targeted second-generation ASOs. | |
| 540 | |a Springer Science+Business Media New York, 2014 | ||
| 690 | 7 | |a PK-PD model |2 nationallicence | |
| 690 | 7 | |a Antisense oligonucleotides |2 nationallicence | |
| 690 | 7 | |a Apolipoprotein B |2 nationallicence | |
| 690 | 7 | |a Time-delay |2 nationallicence | |
| 700 | 1 | |a Shimizu |D Ryosuke |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | |
| 700 | 1 | |a Kitade |D Mikiko |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | |
| 700 | 1 | |a Kobayashi |D Takashi |u Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi Innovation Center for Drug Discovery, Shionogi & Co., Ltd., Sapporo, Japan |4 aut | |
| 700 | 1 | |a Hori |D Shin-Ichiro |u Biotechnology-Based Medicine, Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | |
| 700 | 1 | |a Watanabe |D Ayahisa |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | |
| 773 | 0 | |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/1(2015-02-01), 67-77 |x 1567-567X |q 42:1<67 |1 2015 |2 42 |o 10928 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10928-014-9398-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10928-014-9398-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shimizu |D Ryosuke |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kitade |D Mikiko |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kobayashi |D Takashi |u Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi Innovation Center for Drug Discovery, Shionogi & Co., Ltd., Sapporo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hori |D Shin-Ichiro |u Biotechnology-Based Medicine, Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Watanabe |D Ayahisa |u Drug Metabolism & Pharmacokinetics, Drug Developmental Research Laboratories, Shionogi & Co., Ltd., Toyonaka, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Journal of Pharmacokinetics and Pharmacodynamics |d Springer US; http://www.springer-ny.com |g 42/1(2015-02-01), 67-77 |x 1567-567X |q 42:1<67 |1 2015 |2 42 |o 10928 | ||